LAVA Therapeutics NV — Investor Presentation (August 2023)
43 slides from LAVA Therapeutics NV's investor presentation, Aug 15, 2023
Slide 1: Gamma-delta T cell engagers for the development of next-generation cancer therapeutics
Gamma-delta T cell engagers for the development of next-generation cancer therapeutics Corporate Presentation August 2023
Slide 2: Legal Disclosure: Forward-looking Statements
Legal Disclosure: Forward-looking Statements 2 This presentation contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this presentation can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expe
Slide 3: Pioneering Next-Generation Cancer Therapeutics
Pioneering Next-Generation Cancer Therapeutics ©LAVA Therapeutics 2023 3 • Bispecific antibody platform to engage V9V2 T cells for highly specific tumor cell killing – Leverage the unique quality of V9V2 T cells to selectively kill tumor cells – Gammabody® combines potent tumor cell killing with
Slide 4: Gammabody Pipeline: Potential in Hematological and Solid Tumor Indications
MM: multiple myeloma CLL: chronic lymphocytic leukemia AML: acute myeloid leukemia PSMA: prostate-specific membrane antigen EGFR: epidermal growth factor receptor mCRPC: metastatic castration-resistant prostate cancer Gammabody® Pipeline: Potential in Hematological and Solid Tumor Indications 4 ©LAV
Slide 5: Team Led by Experienced Leaders in the Biotech and Pharma Field
Ton Adang, PhD CDO • Vast experience in drug development • Extensive experience in product discovery and project management (e.g., KEYTRUDA) HansvanderVliet,MD,PhD CSO • Inventor of LAVA’s gamma-delta T cell engager platform • Medical oncologist, extensive experience in preclinical and clinical rese
Slide 6: LAVA's Proprietary Gammabody Platform: Bispecific Gamma-Delta T Cell Engagers
LAVA’s Proprietary Gammabody® Platform Bispecific Gamma-Delta T Cell Engagers
Slide 7: Enthusiasm for Bispecific T Cell Engagers
glofitamab (DLBCL) Approved in the US in 2023 Source: The Antibody Society Data as of May 31, 2023 ©LAVA Therapeutics 2023 7 • High expectations for T cell bispecific therapies driving significant development • 200+ bispecific antibodies in the clinic, 6 bsTCEs currently approved Enthusiasm for Bisp
Slide 8: Enthusiasm for Bispecific T Cell Engagers: Narrow Therapeutic Window
• High expectations for targeted T cell therapies in cancer, but often: – Narrow therapeutic window: – Cytokine Release Syndrome – On-target/off-tumor-related toxicities – Activates immunosuppressive T cells – Sporadic efficacy in solid tumors therapeutic window therapeutic effect toxic effect ©LAVA
Slide 9: Strategies for Widening the Therapeutic Window
• Selecting ‘tumor-specific’ targets • Step-dosing / subcutaneous dosing • Decreasing affinity for T cells • Masking/site-specific activation • Recruiting alternative effector cells • Address only narrow target range, and/or • Cumbersome, and/or • Strongly decrease potency ©LAVA Therapeutics 2023 9
Slide 10: Bispecific γδ T cell-engagers harness innate and adaptive immunity
Bispecific T cell-engagers aim to harness innate & adaptive immunity • Largest -T cell subset in blood: (~90-95% of total γδ-T cells) • Natural ability to recognize and kill tumor cells • Presence of T cells associated with improved outcomes in cancer patients • Recognize tumors through phos
Slide 11: Systemic Activation of Vγ9Vδ2 T Cells Showed Promise
Systemic Activation of V9V2 T Cells Showed Promise • Systemic activation and proliferation via treatment with V9V2 T cell-based therapy (synthetic phosphoantigens (BrHPP) / aminobisphosphonates ± low-dose IL-2) Early attempts with V9V2 T cell-based therapy showed promise, but efficacy may have
Slide 12: Off-the-Shelf Gammabody Platform: Directing Vγ9Vδ2 T Cells to Cancer Cells
Off-the-Shelf Gammabody® Platform: Designed to Enhance Innate Tumor Recognition by Directing V9V2 T Cells to the Cancer Cells LAVA’s Gammabody® designed ti directs V9V2 T cells to tumors to induce direct tumor cell killing with high potency and has the potential to trigger a cascade of anti-canc
Slide 13: Cascade of Anti-Cancer Responses – Potential Favorable Therapeutic Window
Cascade of Anti-Cancer Responses – Potential Translation to Favorable Therapeutic Window Efficacy: • Potent killing of cancer cells (EC50s in the low picomolar range) • No co-activation of immune-suppressive Tregs which dampen antitumor efficacy of cytotoxic T cells • Orchestrate innate and adaptive
Slide 14: Expansion & Cascade Response Without Treg Activation in Preclinical Models
Gammabody® can induce robust gamma delta T cell expansion and can amplify the anti-tumor immune response via downstream activation of other immune cells while avoiding co-activation of immunosuppressive T cells such as Tregs Expansion Cascade Response No Treg Activation Gammabody™ - Mediated Expansi
Slide 15: Gammabody Can Selectively Kill Cancer Cells While Sparing Healthy Cells
• 2:1 ratio ( T cells : Target cells) • Similar CD20 expression levels on C1R neo and B-cells Preferential killing of cancer versus healthy cells demonstrated in vitro and ex vivo; May prevent on-target/off-tumor mediated toxicity and allow for targeting of widely expressed tumor associated antige
Slide 16: LAVA-1207 Gammabody Targeting PSMA for the Treatment of mCRPC
LAVA-1207 Gammabody® Designed to Activate V9V2 T Cells by Targeting PSMA for the Treatment of mCRPC
Slide 17: LAVA-1207: PSMA-targeting Gammabody for Prostate Cancer
LAVA-1207: PSMA-targeting Gammabody® for Prostate Cancer Format • Contains a Fc domain for extended plasma half-life; silenced to avoid off-target T cell activation • Small size (compared to regular IgG antibodies) to facilitate tumor penetration Mechanism of Action • Specifically directs V9V2 T c
Slide 18: Prostate Cancer Epidemiology
18 Prostate Cancer Epidemiology Cancer.Net® FMI (Future Market Insights) ©LAVA Therapeutics 2023 Prostate Cancer − Most frequently diagnosed cancer in males (estimated 288,300 in the United States in 2023) − Second leading cause of cancer deaths in males (estimated 34,700 in the United States in 202
Slide 19: mCRPC – Existing Treatment Options
19 mCRPC – Existing Treatment Options ©LAVA Therapeutics 2023 PARPi’s monotherapy or in combination in BRCAmut +ve 1L (~30,000) Docetaxel or androgen receptor pathway inhibitor (ARPI) (abiraterone, enzalutamide) 2L (~20,000) Docetaxel or ARPI (depending on prior treatment) 3L+ (~10,000) Cabazitaxel,
Slide 20: PSMA-Selected Targeted Agents Landscape
20 PSMA-Selected Targeted Agents Landscape ©LAVA Therapeutics 2023 PSMA-targeted radioligands Drug Study Patient Population N Clinical Results Common Adverse Events Current Status 177Lu-PSMA vs BSOC VISION mCRPC post 1+ ARPI and 1+ taxane 551 vs 280 ORR: 30 vs 2% PSA50: 46 vs 7 % Median OS: 15.3 vs
Slide 21: LAVA-1207 – Phase 1/2a Study Design
LAVA-1207 – Phase1/2a Study Design 21 • Dose escalation in patients with mCRPC (EudraCT 2021-001789-39; NCT05369000) • Primary objectives: investigate safety and tolerability of LAVA-1207 • Secondary objectives: evaluate PK, PD, immunogenicity and preliminary signs of antitumor activity • LAVA-1207
Slide 22: LAVA-1207 – Patient Baseline Characteristics
LAVA-1207 – Patient Baseline Characteristics 22 N=20 ASCO GU 2023 abstract #153 Data on file: LAVA Therapeutics N.V ©LAVA Therapeutics 2023 Data cut-off date: 8 Dec 2022 Patient Baseline Characteristics Age, median (range) 68 (51-76) Years since diagnosis, median (range) 9 (3-21) Prior systemic ther
Slide 23: LAVA-1207 – Time on Treatment
LAVA-1207 – Time on Treatment ASCO GU 2023 abstract #153 Data on file: LAVA Therapeutics N.V ©LAVA Therapeutics 2023 23 • Patients were treated with LAVA-1207 with treatment duration ranging from 4 to 38 weeks • Subsequent to ASCO GU 2023 presentation, LAVA has completed recruitment for dose levels
Slide 24: LAVA-1207 – Initial Phase 1 Data - Safety
0 20 40 60 Fatigue Fever Nausea Anemia Constipation Back pain Pain AST increase Alkaline phosphatase increase Vomiting Anorexia Fall Tumor pain Hematuria Tingling Infusion related reaction Diarrhea Dry mouth Dyspepsia Dyspnea Edema Cytokine release syndrome Chills Flu-like symptoms Hot flashes Hyper
Slide 25: LAVA-1207 – Pharmacokinetics
LAVA-1207 – Pharmacokinetics • Pharmacokinetics of LAVA-1207 appears linear • Data cut-off date: 8 Dec 2022 25 0 24 48 72 96 120 144 168 1,000 10,000 Dose level 4 Time since infusion start (h) LAVA-1207 (ng/L) 5000 N303 N304 N305 0 24 48 72 96 120 144 168 1,000 10,000 Dose level 5 Time since infusio
Slide 26: LAVA-1207 – Pharmacodynamics
LAVA-1207 – Pharmacodynamics • Pharmacodynamics reflect changes expected as per MoA − Pronounced drop in V9V2-T cell frequency 2 hr after dosing, suggesting V9V2-T cell re-distribution, with subsequent recovery − V9V2-T cell activation markers (CD25 and CD69) upregulated following dosing − Rec
Slide 27: LAVA-1207 Preliminary Signs of Anti-Tumor Activity
LAVA-1207 27 Preliminary signs of anti-tumor activity were observed, with iRECIST stable disease (iSD) in 8 out of 14 evaluable patients at week 8 and PSA levels stabilizing or decreasing in heavily pre-treated patients 27 Patient N304 – 40 g • Largest overall decrease in PSA was 61% (46% vs baseli
Slide 28: Addition of IL-2 Supports Gammabody Induced Vγ9Vδ2 T Cell Proliferation
28 T cell TCR triggering: upregulation of high-affinity IL-2R Addition of IL-2 supports Gammabody® induced Vγ9Vδ2 T cell proliferation IL-2 binds to IL-2R complex and promotes proliferation IL-2 supports Gammabody® induced expansion of V9V2 T cells ©LAVA Therapeutics 2023 IL-2 immunomodulation has
Slide 29: Summary of Initial Phase Data
Summary of Initial Phase 1 Data • LAVA-1207 reached a dose of 120 g (starting dose 1.5 g) without the occurrence of high-grade (>2) CRS or DLTs in therapy refractory mCRPC patients – Frequency and severity of AEs do not appear to be dose-dependent – Most observed AEs were not suspected to be relat
Slide 30: LAVA-051 Targets CD1d for the Potential Treatment of CLL, MM & AML
LAVA-051 Targets CD1d to Activate V 9V2 T Cells and iNKT Cells for the Potential Treatment of CLL, MM & AML
Slide 31: LAVA-051: First-in-Class Gammabody Targeting CD1d
Format • Humanized bispecific single domain antibody (bsVHH) of 27kDa ‒ Short plasma half-life, prolonged functional half-life through high affinity TCR binding Mechanism of Action • Engages V9V2 T cells to mediate potent killing of CD1d-expressing tumor cells – CD1d is expressed on tumor cells in
Slide 32: LAVA-051 – Phase 1 Data Confirms MoA in Patients with MM and CLL
02 4 6 8 0.0 0.2 0.4 0.6 0.8 1.0 20 40 60 80 100 120 V9V2 T cell frequency Cohort 2 pt 02-001 Treatment days % of CD3+ 0 2 4 6 8 12 0 20 40 60V9V2 T cell activation Cohort 2 pt 02-001 Treatment days % CD25+ 0 2 4 6 8 0 5 10 15 20 25 V9V2 T cell RO Treatment days %RO 3 μg 15 μg 45 μg (1 pt) 32
Slide 33: LAVA-051 – Potential Signs of Activity
LAVA-051 – Potential Signs of Activity CLL • Patient with R/R CLL (15 g) • Temporary enlargement and tenderness of several involved lymph nodes accompanied by grade 2 fever during Cycle 1 ‒ Resembled a tumor-flare reaction, as reported in CLL with lenalidomide • Patient assessed as having stable di
Slide 34: LAVA-051 – Preliminary Conclusions
LAVA-051 – Preliminary Conclusions • Phase 1 trial supports MoA and safety of the Gammabody® platform − Binding and activation of V9V2 T cells and associated effects on tumors • Trial for relapsed or refractory CLL and MM to be discontinued − Trial ended due to challenging enrollment; highly compe
Slide 35: SGN-EGFRd2 (LAVA-1223) – Licensed to Seagen
SGN-EGFRd2 (LAVA-1223) – Licensed to Seagen Gammabody® for the treatment of EGFR-expressing solid tumors
Slide 36: SGN-EGFRd2 (LAVA-1223) – EGFR-Targeting Gammabody
SGN-EGFRd2 (LAVA-1223) – EGFR-Targeting Gammabody® Format • Gammabody® containing a silenced Fc domain Mechanism of Action • Induces preferential lysis of EGFR-expressing tumor cells while relatively sparing EGFR-expressing normal cells Status • IND cleared • Phase 1 Study in Advanced Solid Tumors e
Slide 37: Janssen Collaboration
Janssen Collaboration Lead Candidate in Development Toward Clinic
Slide 38: Janssen Collaboration
Janssen Collaboration 38 • Lead candidate, aimed at an undisclosed tumor-associated antigen, has been chosen for further development toward clinical studies − In May 2020, LAVA entered into a research collaboration and license agreement with Janssen for the discovery and development of a novel bispe
Slide 39: CD123 Targeting Gammabody for Hematologic Malignancies: LAVA-1266
CD123 Targeting Gammabody® for the Treatment of Hematologic Malignancies LAVA-1266
Slide 40: LAVA-1266: CD123-Targeting Gammabody
• In Development for Treating Hematological Malignancies • Mechanism of Action − Induces preferential lysis of CD123-expressing tumor cells while relatively sparing CD123-expressing normal cells • CD123 is overexpressed in a wide range of hematological malignancies LAVA-1266: CD123-Targeting Gammabo
Slide 41: Anticipated Milestones & Recent Updates
Anticipated Milestones & Recent Updates
Slide 42: Gammabody Pipeline: Potential in Hematological and Solid Tumor Indications
MM: multiple myeloma CLL: chronic lymphocytic leukemia AML: acute myeloid leukemia PSMA: prostate-specific membrane antigen EGFR: epidermal growth factor receptor mCRPC: metastatic castration-resistant prostate cancer Gammabody® Pipeline: Potential in Hematological and Solid Tumor Indications 42 ©LA
Slide 43: Gamma-delta T cell engagers for the development of next-generation cancer therapeutics
Gamma-delta T cell engagers for the development of next-generation cancer therapeutics Corporate Presentation August 2023
LAVA Therapeutics — Investor Presentation (August 2023) on 6ix